Drug repurposing: Ibrutinib exhibits immunosuppressive potential in organ transplantation.

ABSTRACT: Long-term administration of classic immunosuppressants can induce severe adverse effects. The development of novel immunosuppressants confronts great challenges and opportunities. Ibrutinib, an approved drug for B-cell lineages and chronic graft versus host disease (cGVHD), exhibits immunosuppressive efficacy in autoimmune diseases. Ibrutinib's potential as an immunosuppressant in organ transplantation has not been investigated to date. In a xeno-artery patch model ex vivo, ibrutinib inhibited the proliferation of PBMCs (POD 14-42), mainly CD3⁺CD4⁺ and CD3⁺CD8⁺ T cells ex vivo. The secretion of cytokines (IL-6, IL-2 and IFN-γ) was suppressed in response to ibrutinib. In allo-skin transplantation models, ibrutinib delayed the rejecti

SUBMITTER: Zhang Q 

PROVIDER: S-EPMC6097265 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature